BridgeMD
New treatment option for Prostate Cancer Metastatic
Official title Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
ClinicalTrials.gov ID: NCT05457699
What this study is testing
- What it's testing
- This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy, defined by the absence of PSA progression, and who are eligible for MDRT.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults, men only
You may be able to join if
- Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate.
- Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy.
- PSA non-progressing
- ECOG 0-2
- Metastatic disease suitable for MDRT.
You likely can't join if
- Planned intermittent systemic therapy.
- Planned radio-ligand therapy.
See the full eligibility criteria
- Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate.
- Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy.
- PSA non-progressing
- ECOG 0-2
- Metastatic disease suitable for MDRT.
- Primary tumor must have received definitive local treatment (surgery or radiotherapy) with no evidence of local recurrence, or be planned for treatment at the time of MDRT.
- Planned intermittent systemic therapy.
- Planned radio-ligand therapy.
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.